SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001626199-23-000123
Filing Date
2023-11-14
Accepted
2023-11-14 16:18:34
Documents
14
Period of Report
2023-11-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K alpn-20231114.htm   iXBRL 8-K 31349
2 EX-99.1 ex991_20230930.htm EX-99.1 83016
6 alpineislogosma11.jpg GRAPHIC 15826
  Complete submission text file 0001626199-23-000123.txt   278275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT alpn-20231114.xsd EX-101.SCH 1953
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT alpn-20231114_lab.xml EX-101.LAB 24851
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT alpn-20231114_pre.xml EX-101.PRE 13084
8 EXTRACTED XBRL INSTANCE DOCUMENT alpn-20231114_htm.xml XML 2827
Mailing Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102
Business Address 188 EAST BLAINE ST., SUITE 200 SEATTLE WA 98102 206-788-4545
ALPINE IMMUNE SCIENCES, INC. (Filer) CIK: 0001626199 (see all company filings)

IRS No.: 208969493 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37449 | Film No.: 231406621
SIC: 2834 Pharmaceutical Preparations